Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sequana -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (312)	11/3/1997 9:19:00 AM
From: tonyt	Read Replies (1) \| Respond to of 337

Based on ARRS' closing price, SQNA is valued at 16

To: Hippieslayer who wrote (312)	11/3/1997 5:54:00 PM
From: Boyce Burge	Read Replies (2) \| Respond to of 337

Is this merger really a good idea? Much as I like what Sequana is doing in genomics, it has been a disapointment as an investment... and so has Arris. I think the major shareholders of both companies hope that some wonderful synergies will develop - or at least that there will be such a perception among investors. It would be nice if that happens... but I dont think it will anytime soon. This ARRS-SQNA is trying to become a mini Merck, and my instinct is that that will be a slow process. So I'm voting no, for now, on this merger.